Rash News and Research

RSS

Malarial drug shows promise in stopping breast cancer

A malarial drug is showing promise in stopping breast cancer before it starts, Mason researchers are discovering during a clinical trial.

2 Nov 2012

Scientists hope to unravel mystery of how Borrelia burgdorferi causes Lyme disease

Investigators at The University of Texas Health Science Center at Houston (UTHealth) have accelerated the search for the bacterial genes that make the Lyme disease bacterium so invasive and persistent. The discovery could advance the diagnosis and treatment of this disease, which affects an estimated 30,000 Americans each year.

29 Oct 2012

Anxiety related to Medicare physician payment chills doctors' interest in experiments and demonstration programs

A survey by the Medical Group Management Association concluded that physicians' willingness to try new models of payment and delivery -- such as accountable care organizations and bundled payments -- is linked to congressional efforts to fix the Medicare doctor payment formula.

25 Oct 2012

Warning against colloids in fluid resuscitation

Hydroxyethyl starch offers no benefits over saline for fluid resuscitation in critically ill patients and may have renal consequences, shows a randomized trial.

23 Oct 2012

Halloween safety tips from UC San Diego

The Regional Burn Center and Emergency Departments at UC San Diego Health System - along with the California Poison Control System - San Diego Division located at UC San Diego Medical Center - offer the following safety precautions to help parents and guardians make Halloween safe this year.

23 Oct 2012

Blocking leukotriene B4 might slow down eczema

More than 15% of children suffer with eczema, or atopic dermatitis, an inflammatory skin disease that in some cases can be debilitating and disfiguring. Researchers reporting in the October issue of Immunity have discovered a potential new target for the condition, demonstrating that by blocking it, they can lessen the disease in mice.

12 Oct 2012

InterMune receives Health Canada approval for Esbriet to treat idiopathic pulmonary fibrosis

InterMune, Inc. today announced that Health Canada has approved Esbriet (pirfenidone) for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in adult patients.

3 Oct 2012

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma.

1 Oct 2012

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

ARIAD Pharmaceuticals, Inc. today announced the initial clinical results on its investigational, tyrosine-kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.

29 Sep 2012

Abbott receives FDA approval for Humira to treat ulcerative colitis

The U.S. Food and Drug Administration today expanded the approved use of Humira (adalimumab) to include treatment of moderate-to-severe ulcerative colitis in adults.

29 Sep 2012

Shingles becoming more common in Australia

The herpes zoster virus, which causes shingles, is becoming more common as the population ages. In Australia the number of cases has doubled between 2000 and 2010. Hospital emergency departments report a 2–6% increase in cases per year.

28 Sep 2012

New spray could help avoid contact dermatitis

With more than half of all adults allergic to poison ivy, oak and sumac, scientists are reporting an advance toward an inexpensive spray that could reveal the presence of the rash-causing toxic oil on the skin, clothing, garden tools, and even the family cat or dog. Using the spray, described in ACS' The Journal of Organic Chemistry would enable people to wash off the oil, or avoid further contact, in time to sidestep days of misery.

27 Sep 2012

Age at onset influences juvenile dermatomyositis course

Children diagnosed with juvenile dermatomyositis at age 3 years or earlier have milder symptoms than patients with later onset, research suggests.

24 Sep 2012

Global trade pressures may heighten disease incidence

The pressures of global trade may heighten disease incidence by dictating changes in land use. A boom in disease-carrying ticks and chiggers has followed the abandonment of rice cultivation in Taiwanese paddies, say ecologist Chi-Chien Kuo and colleagues, demonstrating the potential for global commodities pricing to drive the spread of infections.

24 Sep 2012

Low income and minority households more likely to have child with undiagnosed food allergy

More can be done to properly manage the care of American children with food allergies, especially when it comes to diagnostic testing and recognizing non-visual symptoms of severe allergic reactions, according to a new Northwestern Medicine study.

14 Sep 2012

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

The drug telaprevir has been available for treatment of chronic hepatitis C infection of genotype 1 since autumn 2011. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether telaprevir offers an added benefit compared with the present standard therapy.

6 Sep 2012

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

Antibiotics are medicines used to treat infections or diseases caused by bacteria, such as some respiratory tract infections (including pneumonia and whooping cough), urinary tract infections, skin infections and infected wounds.

6 Sep 2012

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).

6 Sep 2012

FDA approves Bosulif to treat chronic myelogenous leukemia

The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.

5 Sep 2012

Vandetanib shows efficacy in thyroid cancer

The tyrosine kinase inhibitor vandetanib could significantly extend progression-free survival in patients with locally advanced or metastatic differentiated radioiodine-refractory thyroid cancer, show results of a small phase II randomized trial.

24 Aug 2012

Rash News and Research

Malarial drug shows promise in stopping breast cancer

Scientists hope to unravel mystery of how Borrelia burgdorferi causes Lyme disease

Anxiety related to Medicare physician payment chills doctors' interest in experiments and demonstration programs

Warning against colloids in fluid resuscitation

Halloween safety tips from UC San Diego

Blocking leukotriene B4 might slow down eczema

InterMune receives Health Canada approval for Esbriet to treat idiopathic pulmonary fibrosis

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

Abbott receives FDA approval for Humira to treat ulcerative colitis

Shingles becoming more common in Australia

New spray could help avoid contact dermatitis

Age at onset influences juvenile dermatomyositis course

Global trade pressures may heighten disease incidence

Low income and minority households more likely to have child with undiagnosed food allergy

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

FDA approves Bosulif to treat chronic myelogenous leukemia

Vandetanib shows efficacy in thyroid cancer

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News